CORE B: Clinical Core

核心 B：临床核心

• 批准号: 9402325
• 负责人: DANIEL WEINTRAUB
• 金额: $ 34.96万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-06-15 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9402325
• 关键词: Aging; Bioinformatics; Biological Markers; Biometry; Blood; Blood specimen; Brain; Brain Diseases; Centers of Research Excellence; Church; Clinical; Clinical Data; Clinical Research; Clinical assessments; Cognition; Cognitive; Collection; Common Data Element; Communities; Community Outreach; Consensus; Consent; DNA; Data; Data Analyses; Data Collection; Data Quality; Databases; Dementia; Deposition; Diagnosis; Disease; Education; Education and Outreach; Ensure; Faculty; Family; Foundations; Funding; General Population; Genetic; Goals; Health Fairs; Health Personnel; Heterogeneity; Image; Institutes; Interdisciplinary Study; International; Letters; Lewy Bodies; Lewy Body Dementia; Link; Long-Term Care; Magnetic Resonance Imaging; Mediating; Medical; Medical center; Motor; Movement Disorders; Multicenter Studies; Multiple System Atrophy; National Institute of Neurological Disorders and Stroke; Nerve Degeneration; Neurodegenerative Disorders; Neuropsychological Tests; Parkinson Disease; Parkinson' s Dementia; Participant; Pathologic; Patients; Pennsylvania; Philadelphia; Physicians; Plasma; Positron-Emission Tomography; Procedures; Process; Protocols documentation; RNA; Recruitment Activity; Research; Research Personnel; Research Support; Resources; Source; Standardization; System; Training; Training and Education; Translational Research; Universities; Veterans; Woman; Work; alpha synuclein; biomedical referral center; brain tissue; clinical Diagnosis; clinical biomarkers; data integrity; data management; data sharing; ethnic minority population; interest; medical schools; mild cognitive impairment; nervous system disorder; neuroimaging; neuropathology; next generation; non-demented; non-motor symptom; precision medicine; programs; progressive neurodegeneration; racial and ethnic; repository; synucleinopathy; translational scientist; underserved minority

CORE: Clinical Core B Core Leader: Daniel Weintraub Core Investigators: Lama Chahine, Nabila Dahodwala, James F Morley, Alice Chen-Plotkin Project Summary/Abstract Clinical Core B of this NINDS Morris K. Udall Parkinson's Disease Research Center of Excellence (Udall Center) at the University of Pennsylvania (UPenn) Perelman School of Medicine will be crucial to accomplishing the goals of this multidisciplinary research program. The overarching theme of this UPenn Udall renewal is to elucidate mechanisms of alpha-synuclein (a-syn) mediated progression, heterogeneity and neurodegeneration linked to distinct a-syn strains in Lewy body disorders (LBD) and related synucleinopathies, as well as to advance assessment and treatment towards a precision medicine approach for these disorders. The primary goals of our Udall Center are to elucidate mechanisms of progressive neurodegeneration, with a focus on cognition and other non-motor symptoms, in LBD and related synucleinopathies, including Parkinson's disease (PD) without and with dementia (PDD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), that we hypothesize are linked to different a-syn strains. Core B primary aims are to: (1) recruit, retain and assess research participants for Udall projects I-IV by utilizing NINDS-recommended Common Data Elements (CDEs) and entering/uploading data into the Data Management Resource (DMR) using the Protocol and Forms Research Management System (ProFoRMS); (2) collaborate with Core A to educate the medical community and general public on LBD/MSA and related disorders, and to train the next generation of PD clinical and translational researchers; (3) collaborate with Core C to recruit existing Udall participants with LBD/MSA and related disorders for brain donation, and to assess them longitudinally antemortem to optimize clinicopathological correlations, and, as required, to send collected biosamples to NINDS Biospecimen Exchange for Neurological Disorders or Diseases (BioSEND); and (4) collaborate with Core D to contribute high-quality clinical and biomarker data to the UPenn Integrated NeuroDegenerative Disease Database (INDD), determine the most appropriate data analyses for all clinically-oriented studies, and facilitate sharing of clinical and biomarker data within and outside of UPenn.

CORE：临床核心B 核心领导人：丹尼尔温特劳布 核心研究者：Lama Chahine、Nabila Dahodwala、James F莫利、Alice Chen-Plotkin 项目总结/摘要 该NINDS的临床核心B。Udall Parkinson's Disease Research Center of Excellence（Udall） 宾夕法尼亚大学佩雷尔曼医学院（UPenn Perelman School of Medicine）将是至关重要的 实现这一多学科研究计划的目标。这个宾夕法尼亚大学尤德尔分校的首要主题是 更新的目的是阐明α-突触核蛋白（α-syn）介导的进展、异质性和 与路易体病症（LBD）和相关的突触核蛋白病中的不同a-syn菌株相关的神经变性， 以及推进对这些疾病的精确医学方法的评估和治疗。 我们尤德尔中心的主要目标是阐明进行性神经退行性变的机制， 专注于认知和其他非运动症状，在LBD和相关的突触核蛋白病，包括 帕金森病（PD）不伴痴呆（PDD）、路易体痴呆（DLB）和多发性痴呆（MRD）。 系统萎缩（MSA），我们假设与不同的α-syn菌株有关。核心B主要目标是： (1)利用NINDS建议的方法为Udall项目I-IV招募、保留和评估研究参与者 通用数据元素（CDE）和将数据输入/上传至数据管理资源（DMR） 使用协议和表格研究管理系统（ProFoRMS）;（2）与核心A合作， 教育医学界和公众关于LBD/MSA和相关疾病，并培训下一个 产生PD临床和转化研究人员;（3）与核心C合作，招募现有的Udall 参与者与LBD/MSA和相关疾病的脑捐赠，并评估他们纵向 以优化临床病理学相关性，并根据需要将收集的生物样本发送给 NINDS神经系统疾病或疾病生物标本交换（BioSEND）;以及（4）与 核心D为UPenn综合神经退行性疾病提供高质量的临床和生物标志物数据 疾病数据库（INDD），为所有临床研究确定最合适的数据分析，以及 促进临床和生物标志物数据在宾夕法尼亚大学内外的共享。